Analysis
As of Thursday, November 19, 2026, Sanofi is weighing an acquisition of Insmed, a deal for a company with a $26.3 billion market cap, Bloomberg reported, citing people familiar with the matter. Sanofi is speaking with advisers, deliberations are ongoing and any transaction could still be weeks away, according to the report as summarized by Seeking Alpha on TradingView. Insmed soared 15% and Sanofi's ADRs fell 3%. There is no guarantee of a deal, other bidders could emerge, and both companies declined to comment to Bloomberg.
What Insmed does
Insmed is headquartered in Bridgewater, New Jersey, and sells two drugs: BRINSUPRI (brensocatib) and ARIKAYCE (amikacin liposome inhalation suspension), per the company's first-quarter 2026 results release. Brinsupri is the reason a buyer would pay up: in that release Insmed guided to at least $1 billion of Brinsupri revenue for 2026.
Insmed revenue: how fast is Brinsupri growing?
The third quarter showed the launch still growing in dollars, with nearly all Brinsupri sales in the U.S. and a Japan launch in October, The Private Banker reported. The quarter by quarter numbers:
“Brinsupri is the reason a buyer would pay up: in that release Insmed guided to at least $1 billion of Brinsupri revenue for 2026.”
- Q1 2026 -- total revenue $306.0 million; Brinsupri $207.9 million, Arikayce $98.1 million (Insmed release)
- Q2 2026 -- Brinsupri $309.2 million (The Private Banker)
- Q3 2026 -- total revenue up 268% to $524.4 million; Brinsupri $400.1 million, up 29% sequentially; Arikayce $124.4 million, up 9% year over year (The Private Banker)
- 2026 Brinsupri guidance -- raised at the low end to $1.35 billion to $1.4 billion, from $1.25 billion to $1.4 billion (The Private Banker)
The growth rate is slowing, though. Brinsupri's two prior post-launch quarters grew 44% and 49% sequentially, against 29% in the third quarter, and Insmed posted a loss of $0.46 a share, wider than the $0.34 analysts expected, per the same report.
Why Sanofi wants a US growth asset
Sanofi's growth leans on one drug. Dupixent sales rose 37.6% to EUR 5.2 billion in the second quarter of 2026, above EUR 5 billion a quarter for the first time, Sanofi reported. An Insmed deal would be a different size from the deals Sanofi usually does: Sanofi's market value is about EUR 101.3 billion, or $111.3 billion, so Insmed's equity value is nearly a quarter of Sanofi's, per The Private Banker, which noted that Sanofi's past bolt-on deals typically ran to a few billion dollars.
Value Add VC data
Insmed is a public company, so there are no recent private rounds to list, and no takeover price has been set. Comparable deals:
- Sanofi and Dynavax -- Sanofi completed a $2.2 billion acquisition of the vaccines company (DCAT Value Chain Insights)
- Palo Alto Networks and Applied Compute -- a $4.5 billion agreement this week, outside pharma, as Pulse covered on Nov 18
A bid at or above Insmed's $26.3 billion market cap would be more than ten times the Dynavax price, a Pulse calculation.
The risk in a takeover report
A report is not a bid. No price, financing structure or other terms have been disclosed, per The Private Banker, and Bloomberg's sources said a deal could be weeks away. The 15% jump also prices in a premium on a stock that had fallen about 40% over the prior 12 months, per The Private Banker, so a buyer is paying for Brinsupri's trajectory at the point where sequential growth is cooling from 49% to 29%. Insmed is scheduled to present at the Evercore ISI 9th Annual Healthcare Conference on December 1, per Seeking Alpha, the next public venue where management could be asked about Sanofi.